334-42-9

Basic information

• Product Name: 1-bromo-7-fluoroheptane
• Synonyms: 1-bromo-7-fluoroheptane;1-fluoro-7-broMoheptane
• CAS NO: 334-42-9
• Molecular Formula: C₇H₁₄BrF
• Molecular Weight: 197.0884632
• EINECS: -0
• Mol File: 334-42-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 202.6 °C at 760 mmHg
• Flash Point: 78.9 °C
• Appearance: /
• Density: 1.2240 (rough estimate)
• Refractive Index: 1.4463
• CAS DataBase Reference: 1-bromo-7-fluoroheptane(CAS DataBase Reference)
• NIST Chemistry Reference: 1-bromo-7-fluoroheptane(334-42-9)
• EPA Substance Registry System: 1-bromo-7-fluoroheptane(334-42-9)

Safety Data

• Hazardous Substances Data: 334-42-9(Hazardous Substances Data)

Usage

General Description

1-bromo-7-fluoroheptane is a chemical compound with the molecular formula C7H14BrF. It is a halogenated alkane that contains both bromine and fluorine. 1-bromo-7-fluoroheptane is a clear, colorless liquid with a slightly sweet odor. It is primarily used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. 1-bromo-7-fluoroheptane is also used as a reagent in organic synthesis and as a building block in the production of various chemicals. It is important to handle this compound with caution as it is a hazardous material and can cause irritation to the skin, eyes, and respiratory system.

Upstream product

• 10160-24-4 7-bromoheptyl alcohol 
• 75-09-2 dichloromethane 
• 2695-48-9 8-Bromo-1-octene 
• 408-16-2 7-fluoro-heptan-1-ol 

Downstream Products

• 463-19-4 9-Fluor-non-1-in 
• 374109-41-8 (2-{2-[4-(7-fluoro-heptyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl]-ethoxy}-phenyl)-acetic acid methyl ester 

Relevant articles and documents

Benzoxazinones as PPARγ Agonists. 2. SAR of the Amide Substituent and In Vivo Results in a Type 2 Diabetes Model

A series of benzoxazinones has been synthesized and tested for PPARγ agonist activity. Synthetic approaches were developed to provide either racemic or chiral compounds. In vitro functional potency could be measured through induction of the aP2 gene, a target of PPARγ. These studies revealed that compounds with large aliphatic chains at the nitrogen of the benzoxazinone were the most potent. Substitution of the chain was tolerated and in many cases enhanced the in vitro potency of the compound. Select compounds were further tested for metabolic stability, oral bioavailability in rats, and efficacy in db/db mice after 11 days of dosing. In vivo analysis with 13 and 57 demonstrated that the series has potential for the treatment of type 2 diabetes.

Antiarrhythmic (S)-enantiomers of methanesulfonamides

Compounds of formula (I) and pharmacologically acceptable salts thereof wherein: n is 1 to 3, R is an alkyl, R1 is hydrogen or alkyl, R2 is alkyl, R3 is an alkyl; b) alkyl substituted with an aryl, heteroaryl or cycloalkyl